Lomcap — Lomustine 40 mg, 10 pcs, GLS

Lomcap 40 mg — Lomustine 40 mg Capsules, 10 Capsules

Product code: 489

1500₴ 1700₴ -12% On order · from 14 days
1
Active ingredient
Dosage
40 mg
Dosage form Capsules
Capsules per pack 10

Lomcap 40 mg is a potent antineoplastic agent belonging to the class of alkylating agents (nitrosourea derivatives) indicated for the treatment of central nervous system malignancies and lymphoproliferative disorders. The active pharmaceutical ingredient is lomustine at a strength of 40 mg supplied as hard gelatin capsules (Lomustine Capsules IP 40 mg). The product is developed and manufactured by the Indian pharmaceutical company GLS Pharma Ltd.

Lomustine is a lipid-soluble nitrosourea that readily crosses the blood-brain barrier (BBB), making it a cornerstone chemotherapeutic agent for primary and metastatic brain tumors. Its mechanism of action involves alkylation of DNA and RNA, as well as carbamoylation of cellular proteins, leading to inhibition of nucleic acid synthesis, DNA cross-linking, and subsequent tumor cell apoptosis.

Supplied in a package containing 10 hard capsules (40 mg). Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of Lomcap 40 mg:

  • ✅ Blood-Brain Barrier Penetration: High lipid solubility ensures effective delivery into intracranial tumor tissues.
  • ✅ Convenient Dosing Schedule: Administered orally as a single dose once every 6 weeks, minimizing clinical visit burdens.
  • ✅ Broad Oncologic Spectrum: Highly effective in gliomas, glioblastoma, Hodgkin's lymphoma, and solid tumors.
  • ✅ GLS Pharma Standards: High-grade generic formulation manufactured under stringent international quality guidelines.
  • ✅ Precise 40 mg Strength: Hard capsules facilitate accurate individualized body surface area (BSA) dosing calculations.

Lomcap 40 mg is supplied as hard capsules for oral administration.

Qualitative and Quantitative Composition per Capsule:

  • • Active Ingredient: Lomustine — 40 mg.
  • • Excipients: Formulation fillers and binders (lactose, microcrystalline cellulose, talc, magnesium stearate). Capsule shell: gelatin, titanium dioxide, approved colorants.

Packaging and Presentation: Hard gelatin capsules containing powder or granules. Each package contains 10 capsules (40 mg) along with prescribing information. Labeled with Lomcap (Lomustine Capsules IP 40 mg) and GLS Pharma Ltd corporate graphics.

Pharmacodynamics:
Lomustine is a bifunctional alkylating agent acting via both DNA/RNA alkylation and protein carbamoylation, inhibiting cellular replication. It exhibits no cross-resistance with other alkylating agents. Due to high lipid solubility, lomustine readily crosses the blood-brain barrier into cerebrospinal fluid, accounting for its potent activity against intracranial neoplasms.

Pharmacokinetics:

  • • Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract following oral ingestion. Peak plasma concentrations are achieved within 1 to 4 hours.
  • • Distribution: Widely distributed into body tissues with rapid blood-brain barrier penetration.
  • • Metabolism: Extensively metabolized in the liver into active alkylating metabolites.
  • • Elimination: Excreted predominantly renally as metabolites (approx. 50% within 24 hours) and via feces. Terminal half-life (T1/2) of active metabolites ranges from 16 to 48 hours.

Lomcap 40 mg is indicated in adult patients as monotherapy or in combination regimens for:

  • • Brain Tumors: Primary brain tumors (gliomas, glioblastoma, medulloblastoma, astrocytoma) and brain metastases.
  • • Lymphoproliferative Disorders: Hodgkin's lymphoma (refractory to standard therapies) and non-Hodgkin's lymphomas.
  • • Solid Tumors: Gastric cancer, colorectal cancer (as part of combination chemotherapy).

Lomcap is administered orally as a single dose once every 6 weeks.

Administration Guidelines:
Capsules should be taken on an empty stomach (preferably at bedtime or 3 hours post-meal to mitigate nausea and vomiting), swallowed with plenty of water. Capsules must not be broken, chewed, or opened.

Dosing Regimen:
The standard recommended starting dose for adults and pediatric patients as monotherapy is 100–130 mg/m² body surface area as a single dose every 6 weeks. In patients with compromised bone marrow function, the dose is reduced to 75–100 mg/m².

Administration of Lomcap is contraindicated in:

  • • Hypersensitivity: Known hypersensitivity to lomustine or other nitrosoureas.
  • • Severe Myelosuppression: Baseline severe leukopenia (<3,000 cells/µl) or thrombocytopenia (<75,000 cells/µl).
  • • Severe Renal or Hepatic Impairment: Pronounced liver or kidney dysfunction.
  • • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.

Evaluated drug interactions with lomustine include:

  • • Myelotoxic Agents & Radiation Therapy: Concurrent use with other cytotoxic drugs or radiation therapy significantly exacerbates bone marrow suppression (dose reduction required).
  • • Hepatic Enzyme Inducers/Inhibitors: May alter lomustine metabolism rates.
  • • Alcohol: Consumption of alcohol during therapy is strictly discouraged due to heightened hepatotoxicity and gastrointestinal adverse effects.

Pregnancy:
Lomcap is contraindicated during pregnancy due to proven teratogenic, mutagenic, and embryotoxic potential. Women of childbearing potential and male partners must utilize effective contraception during treatment and for several months post-therapy.

Lactation:
Excretion of lomustine into human breast milk cannot be ruled out. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • • Hematologic Toxicity (Primary Feature): Delayed myelosuppression (leukopenia and thrombocytopenia nadir occur 4 to 6 weeks post-dose; repeat courses must not be administered sooner than every 6 weeks).
  • • Gastrointestinal Tract: Nausea and vomiting (onset 2 to 6 hours post-dose lasting up to 24 hours; antiemetic prophylaxis required), anorexia, stomatitis.
  • • Hepatic Effects: Transient elevations in transaminases, bilirubin, and potential hepatotoxicity risk.
  • • Pulmonary Toxicity: Rare but severe pulmonary fibrosis (interstitial pneumonitis) associated with cumulative long-term use.
  • • Nervous System: Headache, lethargy, ataxia, confusion.

Symptoms:
Acute or chronic overdose manifests as profound bone marrow suppression (severe pancytopenia), nausea, vomiting, stomatitis, diarrhea, and hepatic/renal dysfunction.

Treatment:
No specific antidote exists. Hospitalization, supportive and symptomatic care (blood component transfusions, antibiotic therapy for infections, colony-stimulating factors) should be initiated.

Storage Requirements for Lomcap 40 mg:

  • 🌡️ Temperature Range: Store in a dry place protected from light at temperatures below 25 °C (per package labeling).
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic agent).
  • ⏳ Shelf Life: Stated on packaging. Do not use past expiration date. Prescription-only hospital medicine.

To verify authenticity of genuine Lomcap 40 mg manufactured by GLS Pharma Ltd, inspect the following features:

  • ✅ Corporate Branding: Distinctive GLS Pharma logo and product name printed clearly on outer carton and blister foil.
  • ✅ Packaging Markings: Laser-printed Batch No., manufacturing date, and expiration date matching across carton and blister, displaying Lomcap (Lomustine Capsules IP 40 mg).
  • ✅ Package Integrity: Tamper-evident seals or features (if applicable), high-grade printing without typographical errors.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 14 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 08.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00